Lilly added $5.3 billion to one Indiana plant because it could not make enough tirzepatide

Eli Lilly said it would add $5.3 billion to the $3.7 billion already committed to a plant in Lebanon, Indiana, which company officials called the largest manufacturing investment in a history running back to the 19th century. The site is built for tirzepatide, the active ingredient behind both Mounjaro and Zepbound.

Supply, not appetite for the drugs, is what the money is aimed at. Mounjaro and Zepbound had already generated more than $2 billion in sales in a single quarter while the manufacturer struggled to make enough of them, and analysts tracked by the data firm FactSet expected the pair to clear well over $30 billion in combined annual sales eventually.

An announcement cannot buy time. Ground was broken the previous year, production was not expected until near the end of 2026, and output only advances through 2028. For a person whose prescription keeps coming back unfilled, a supply constraint measured in months is being answered on a schedule measured in years, and the distance between those two clocks is the part a plant announcement cannot close.

Read the full story at AP News ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.